ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Articles tagged "Sirolimus (SLR)"

  • 2018 American Transplant Congress

    Sirolimus Use Improves Cancer-Free Survival Following Transplantation: A Single Center 10-Year Analysis

    P. Chen,2 L. Nair,2 A. Ata,2 D. Conti,1 R. Lopez-Soler.1

    1Surgery, Section of Transplantation, Albany Medical College, Albany, NY; 2Surgery, Albany Medical College, Albany, NY.

    Introduction:In previous published results, we showed that the use of Sirolimus-based immunosuppression regimens had equivalent patient and graft 10-year survival compared to historical controls maintained…
  • 2017 American Transplant Congress

    Determinants of Successful Use of Sirolimus in Renal Transplantation.

    M. Naik,1 W. Gwinner,2 W. Arns,3 E. Basic,10 K. Budde,1 F. Diekmann,4 M. Fischereder,5 J. Goßmann,6 K. Heller,7 N. Heyne,8 J.-S. Jürgensen,1 C. Morath,9 U. Riester.10

    1GSSG, Berlin, Germany; 2GSSG, Hannover, Germany; 3GSSG, Köln, Germany; 4GSSG, Barcelona, Spain; 5GSSG, München, Germany; 6GSSG, Frankfurt, Germany; 7GSSG, Erlangen, Germany; 8GSSG, Tübingen, Germany; 9GSSG, Heidelberg, Germany; 10GSSG - Pfizer, Berlin, Germany

    Sirolimus (SLR) is an established component in the immunosuppressive treatment after renal transplantation.The side effects of SLR differ from other immunosuppressants and may limit its…
  • 2017 American Transplant Congress

    Systemic Meta-Analysis: Is Early Conversion to mTOR Inhibitors Represent a Suitable Choice in Renal Transplant Recipients?

    K. Jayant,1 I. Reccia,2 J. Walton,1 A. Sharma,3 A. Halawa.1

    1Faculty of Health and Sciences, Institute of Learning and Teaching, University of Liverpool, Liverpool, United Kingdom; 2Department of Hepato-Pancreato-Biliary Surgery (HPB), Hammersmith Hospital, Imperial College, London, United Kingdom; 3Sheffield Teaching Hospitals, Sheffield Teaching Hospitals, Sheffield, United Kingdom

    Aim: This meta-analysis focuses on the current evidence of renal graft functioning and graft survival following early conversion to mTOR inhibitors with or without CNI…
  • 2017 American Transplant Congress

    mTOR Inhibitor and Low-Dose Tacrolimus in Pediatric Kidney Transplant (PKT): 9-Years Data of a Bi-Therapy Treatment.

    R. Vilalta, E. Lara, A. Madrid, M. Muñoz, S. Chocron, G. Ariceta.

    Pediatric Nephrology, Hosptal Vall d´Hebron, Barcelona, Spain

    INTRODUCTIONNephrotoxicity , serious infectious, or malignancy risk , curtails tacrolimus use in PKT . However, based on potential antiviral and antitumoral actions of mTOR inhibitor…
  • 2017 American Transplant Congress

    Sirolimus Prolonged Survival After Living Donor Liver Transplantation for HCC Beynd Milan Criteria; Outcome of a Multicenter Prospective Randomized Phase II Trial (ClinicalTrials.gov Identifier: NCT01374750).

    K.-W. Lee,1 S.-H. Kim,2 N.-J. Yi,1 S.-K. Hong,1 G. Yoon,1 H. Kim,1 D. Oh,1 S.-S. Han,2 S.-J. Park,2 K.-S. Suh.1

    1Department of Surgery, Seoul National University, Seoul, Republic of Korea; 2Center for Liver Cancer, National Cancer Center, Goyangsi, Republic of Korea

    Background:It is unclear whether the reported benefit of mTORi in LT for HCC is from direct effect of mTOR inhibitors. We aimed to compare directly…
  • 2017 American Transplant Congress

    Differential Effects of the Novel ATP-Competitive mTOR Inhibitor (TORKinib) AZD2014 and Rapamycin on Alloimmunity and Transplant Survival.

    D. Fantus, Y. Ono, H. Dai, S. Yokota, O. Yoshida, A. Thomson.

    Surgery, Thomas Starzl Transplantation Institute, Pittsburgh, PA

    Background: Rapamycin (RAPA), is an immunosuppressive agent that inhibits the mechanistic target of Rapamycin (mTOR), the kinase subunit of two mTOR- containing complexes (mTORC1 and…
  • 2017 American Transplant Congress

    Impact of Everolimus Added to a De Novo Belatacept Regimen on the Risk of BK Viremia After Kidney Transplant.

    C. Larsen,1 M. Alseiari,2 S. Chandran,2 F. Vincenti,2 D. Wojciechowski.1

    1Division of Nephrology, Massachusetts General Hospital, Boston, MA; 2Division of Nephrology, UCSF, San Francisco, CA

    IntroductionBK viremia is a common complication following kidney transplantation. In vitro data suggest that inhibition of the mTOR–SP6-kinase pathway prevents expression of early viral genes…
  • 2017 American Transplant Congress

    Alternations in Amplitude of Low Frequency Fluctuation in Renal Allograft Recipients That Received Tacrolimus or Sirolimus: An fMRI Study.

    J. Wen,1 X. Ni,1 L. Wu,2 G. Zheng,2 L. Zhang,2 J. Chen.1

    1National Clinical Research Center of Kidney Diseases, Jinling Hospital, Medical School of Nanjing University, Nanjing, China; 2Department of Medical Imaging, Jinling Hospital, Medical School of Nanjing University, Nanjing, China

    Objective The side-effects of resting tremor was common in renal transplant receipts receive tacrolimus. But the mechanism of this side-effect was unknown. This study want…
  • 2017 American Transplant Congress

    DC-SIGN Functionalized Porous Silicon Nanoparticles Targeting to Human and Non-Human Primate Dendritic Cells.

    S. Stead,1 S. Kireta,2 S. McInnes,3 P. Rose,1 S. Jesudason,1,2 S. Grey,4 D. Rojas-Canales,2 R. Carroll,1,2 N. Voelcker,4 P. Coates.1,2

    1Medicine, University of Adelaide, Adelaide, Australia; 2Central and Northern Adelaide Renal and Transplantation Service, Royal Adelaide Hospital, Adelaide, Australia; 3ARC Centre of Excellence in Convergent Bio-Nano Science and Technology, University of South Australia, Adelaide, Australia; 4Transplantation Immunology, Garven Institute of Medical Research, Sydney, Australia

    Porous silicon (pSi) nanoparticles, modified to specifically target DC, provide a novel platform to carry and deliver immunosuppressive drugs. The aim was to conjugate DC-SIGN…
  • 2016 American Transplant Congress

    Effect of Isolated Intraperitoneal Sirolimus Treatment on the Kidneys of C57BL/6 Mice.

    B. Kim,1,3 Y. Cho,3 H. Lee,3 D. Joo,2,3 K. Huh,2,3 M. Kim,2,3 Y. Kim.2,3

    1Nephrology Division, Department of Internal Medicine, Severance Hospital, Yonsei University Health System, Seoul, Republic of Korea; 2Department of Transplantation Surgery, Severance Hospital, Yonsei University Health System, Seoul, Republic of Korea; 3The Research Institute for Transplantation, Seoul, Republic of Korea.

    Sirolimus, a mammalian target of rapamycin inhibitor, is widely used in transplantation. However, the mechanism by which sirolimus induces adverse effects such as proteinuria and…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • Next Page »

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences